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Background: Studies have shown that N-methyl-D-aspartate (NMDA) receptors play a critical 
role in pain processing at different levels of the central nervous system.
Methods: In this study, we used adult Wistar rats to examine gender differences in the effects 
of NR2B NMDA antagonism at the level of the anterior cingulate cortex in phasic pain, and in 
the first and second phases of a formalin test. Rats underwent stereotactic surgery for cannula 
implantation in the anterior cingulate cortex. After recovery, paw withdrawal latency to a nox-
ious thermal stimulus was assessed. Rats were also subjected to a formalin pain test whereby 
60 µL of 5% formalin was injected into the right hind paw.
Results: Female and male rats that received Ro 25-6981, an NR2B antagonist, before formalin 
injection showed significantly reduced pain responses to the formalin test compared with saline-
injected control rats (P , 0.05). No gender differences in phasic pain responses were found in 
rats treated with Ro 25-6981.
Conclusion: These results suggest that cortical antagonism of the NR2B subunit reduces 
inflammatory pain levels in both genders of rat.
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Introduction
N-methyl-D-aspartate (NMDA) receptors from different areas in the central nervous 
system, including the anterior cingulate cortex, are fundamental in the generation of 
inflammatory pain responses.1 Tissues examined in previous studies have included 
the spinal cord, periaqueductal gray matter, and thalamus, and have concluded that 
NMDA receptor agonism generates an increase in the inflammatory pain response.2–6 
In addition, one study has found that a decrease in the activation of NMDA receptors 
by means of genetic or pharmacologic manipulation generates a subsequent decrease 
in the inflammatory pain response.7
Functional NMDA receptors are typically composed of heterogenic NR1, NR2A, 
NR2B, NR2C, NR2D, NR3A, and NR3B subunits.8,9 The NR2A and NR2B subunits 
are highly expressed in the frontal areas of the brain (including the anterior cingulate 
cortex) in rodents and humans.10 One previous study reported that NR2B subunit over-
expression in the insular and anterior cingulate cortices tended to increase inflammatory 
pain without affecting phasic pain responses. These results suggest the potential role 
of the NR2B subunit at the forebrain level, especially the anterior cingulate cortex, 
as a possible strategy for the management of persistent pain conditions.10 Moreover, 
a study by Wu et al reported that peripheral inflammatory pain induces upregulation 
of NR2B receptors at the level of the anterior cingulate cortex, and antagonism of 
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these receptors reduces behavioral sensitization related to 
inflammation in a Freund’s complete adjuvant model in 
male rodents.11
Participation of the anterior cingulate cortex and other 
cortical areas in persistent pain responses has been described 
before. In particular, the anterior cingulate cortex has been 
related to affective components of pain as well as the sen-
sory part of pain and integrative features of pain (affective-
cognition selection of response).12–17 
The long-term potentiation process in the anterior 
cingulate cortex is proposed as the molecular mechanism 
underlying the sensitization of chronic pain conditions. The 
long-term potentiation mechanism involves mainly the excit-
atory neurotransmitter, glutamate, and its postsynaptic recep-
tors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) and NMDA.1,17–19 In addition, some authors 
have proposed specific exploration of NR2B subunit antago-
nism at the level of the anterior cingulate cortex as a strategy 
for reducing persistent pain and side effects in contrast with 
other NMDA antagonists.10,20 Further studies have reported 
gender differences in mechanisms of pain and analgesia 
involving NMDA receptors.21–23 In general, the importance 
of including female groups and their reproductive cycle 
phases in pain research and in other fields of neurobiological 
research has been recognized.24–26
A previous study has demonstrated that Ro 25-6981 is a 
very selective antagonist and activity-dependent blocker of 
NMDA receptors containing the NR2B subunit.27 However, 
there have been few studies exploring gender differences in 
the role of the cortex in pain responses. The objective of the 
present study was to evaluate gender differences in the effects 
of anterior cingulate cortex NR2B receptor antagonism on 
phasic and tonic pain responses.
Materials and methods
Subjects
A total of 86 adult male and female Wistar rats were used. 
The female rats weighed 200–225 g and the male rats 
weighed 275–300 g. Female rats performed their behavioral 
tests in the estrus phase of the estrous cycle. Breeding pairs 
of rats were obtained from Harlan Company (Mexico City, 
Mexico) and bred, housed, and maintained in the animal 
care facilities of the Instituto de Investigaciones Científicas 
Avanzadas y Servicios de Alta Tecnología, Asociación de 
Interés Público (INDICASAT-AIP) according to Public 
Health Service procedures. Animals were housed in light/
dark cycles of 14 hours × 10 hours with water and food ad 
libitum. All the experiments adhered to the guidelines of the 
Committee for Research and Ethical Issues of International 
Association for the Study of Pain.28 Moreover, the scien-
tific work was reviewed by the scientific committee of the 
INDICASAT-AIP.
Stereotactic surgery and infusion
The animals were anesthetized with an intramuscular injection 
of ketamine 75 mg/kg + xylazine 10 mg/kg. Surgery was car-
ried out using stereotactic apparatus. For microinfusion exper-
iments, chronic guide cannulae were implanted according to 
the following procedure: double stainless steel guide cannulae 
(26GA, Plastics One Inc, Roanoke, VA) were implanted 1 mm 
over the anterior cingulate cortex injection site (AP + 2.6, 
D/V −1.6, M/L ± 0.6, Bregma). After chronic guide cannula 
implantation, the holes were closed with dummy cannulae 
of the same extension (0.2 mm, Plastics One Inc). One week 
later, the rats were administered either Ro 25-6981 (Sigma, 
St Louis, MO) or saline infusions through injector cannulae 
(33GA, Plastics One Inc) connected to tubing (PE 20, Plastics 
One Inc) and a Hamilton syringe (Model 7001 Gas Tight, 
Harvard Apparatus, Holliston, MA). All animals included in 
the study recovered adequately from surgery, as verified by 
post-surgery weight measurements.
Drug preparation
Ro 25-6981, an antagonist of the NR2B subunit of the NMDA 
receptor, was prepared in sterilized isotonic saline solution 
(0.9% NaCl). The drug was prepared at a 1 µg/0.5 µL con-
centration and administered at a rate of 0.5 µL/90 seconds 
for a total volume of 0.5 µL per side.29 The drug or vehicle 
(isotonic saline) was administered through a cannula system 
connected to PE 20 tubing and a Hamilton syringe.
Behavioral testing and drug delivery
All the behavioral testing was performed by evaluators 
blinded to the drug treatment administered. In each test, 
the rats had been habituated beforehand to the behavioral 
apparatus (Hargreaves or formalin cages) for 40 minutes 
on three consecutive days.7 Rats were handled by the 
investigator before the test on the same days of apparatus 
habituation. Behavioral experiments were performed dur-
ing light-cycle hours; furthermore, all the animals were 
behaviorally assessed in groups of at least 2–4 rats to avoid 
any effects of isolation analgesia. The injector cannulae 
were left for a period of 20–30 seconds before injection of 
the drug or the saline control, and were left for a period of 
two minutes after injection of the drug. For the Hargreaves 
experiments, behavioral measurements (latencies) were 
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recorded at five minutes for the control and experimental 
groups and at 30 minutes for the experimental groups after 
drug or saline injection. For the formalin test, drug or saline 
infusion was performed 15 minutes before and 25 minutes 
after formalin injection.
Hargreaves test
For the Hargreaves test, the experimental groups used were: 
male controls without surgery (n = 8), female controls 
without surgery (n = 8), males that received saline infusion 
(n = 7), females that received saline infusion (n = 6), males 
that received Ro 25-6981 infusion (n = 7), and females that 
received Ro 25-6981 infusion (n = 7). After cerebral infusion 
of the drug or vehicle, phasic pain responses were assessed 
using the Hargreaves test at five and 30 minutes after infu-
sion.30 Rats were placed in the Plexiglas compartments (12 cm 
height × 21 cm length × 10 cm width) of an analgesiometer 
apparatus (IITC Life Sciences, Woodland Hills, CA). A heat 
source was applied to the plantar surface, and the paw with-
drawal latency of each hind paw was measured at 2–5 minute 
intervals (one latency for each hind paw). A cutoff time of 
15 seconds was established for avoiding tissue   damage. An 
average value was calculated for each rat.
Formalin test
The experimental groups used for the formalin test comprised 
males that received saline infusion before formalin injection 
(n = 10), females that received saline infusion before formalin 
injection (n = 6), males that received Ro 25-6981 infusion 
before formalin injection (n = 7), females that received 
Ro 25-6981 infusion before formalin injection (n = 7), males 
that received Ro 25-6981 infusion after formalin injection 
(n = 8), and females that received Ro 25-6981 infusion 
after formalin injection (n = 5). The formalin test was used 
as a model of the tonic response to inflammatory pain.31–34 
This test was performed 72 hours after the Hargreaves test. 
Rats were injected subcutaneously into the plantar surface 
of the right hind paw with 60 µL of 5% formalin. Cerebral 
infusions of the drug or saline were carried out 15 minutes 
before and 25 minutes after formalin injection. Following 
formalin injection, the behavior of the rats was recorded 
using a digital video camera for a period of 60 minutes. 
Licking and/or biting of the injected hind paw was consid-
ered as an index of pain-related behavior; this behavior was 
recorded and quantified in seconds during time blocks of 
five minutes by two independent and blinded evaluators. 
Later, for each block of five minutes, the average score of 
the two evaluators was calculated.
Cannula verification
After finishing the behavioral experiments, rats were 
administered a lethal dose of ketamine/xylazine and 
received a bilateral infusion of 0.025% methylene blue 
in the anterior cingulate cortex. Immediately after this, 
the rats were perfused with isotonic saline solution (0.9% 
NaCl) via cardiac puncture followed by 4% formaldehyde 
solution. The brains were then extracted and processed as 
described elsewhere29 and analyzed further under a light 
microscope. Only rats with exact cannula location in the 
anterior cingulate cortex were included in this investiga-
tion. The samples included in the accompanying figures 
describe the number of animals that passed the cannula 
verification procedure satisfactorily. Drawings of the his-
tology are presented in the additional material in Supple-
mentary Figure 1.
Statistical analysis
Statistical analysis was performed using analysis of   variance 
with post hoc tests. Statistical significance was set at 
P , 0.05. SPSS version 19 for Windows (SSPS Inc, Chicago, 
IL) was used for the statistical analysis.
Results
No effects of Ro 25-6981 on phasic  
pain responses
The Hargreaves test was used to determine if infusion of Ro 
25-6981 into the anterior cingulate cortex could reduce phasic 
pain levels in rats of both genders and to exclude possible 
motor deficits due to stereotactic surgery. There were no sig-
nificant differences between the experimental groups for mean 
paw withdrawal latency based on repeated-measures analysis 
of variance, ie, time effect (Wilk’s λ = 0.97, F[1,23] = 0.82, 
P = 0.38), gender effect (Wilk’s λ = 1, F[1,23] = 0.02, 
P = 0.96), treatment effect (Wilk’s λ = 1, F[1,23] = 0.08, 
P = 0.79), or interaction effect, ie, time × gender × treatment 
(Wilk’s λ = 0.97, F[1,23] = 0.63, P = 0.43). Moreover, compar-
ing rats that received saline using analysis of variance did not 
find any gender or treatment effects (see Figure 1). This lack 
of difference suggests that stereotactic surgery did not induce 
any secondary or side effects in motor response (that otherwise 
could have been manifested as differences in latency).
Effect of Ro 25-6981 on first and second  
phases of the formalin test
A formalin test was used to evaluate possible gender differ-
ences in the effects of Ro 25-6981 on the first and second 
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phases of the formalin test at different time points (infused 
before or after formalin injection). Gender comparisons of 
tonic pain responses when the drug was infused before for-
malin injection (0–10 minutes and 10–20 minutes in Figure 2) 
did not show any differences between males and females 
(Wilk’s λ = 0.998, F[1,31] = 0.055, P . 0.05). However, 
a gender difference in tonic pain response was seen when 
the drug was infused (30–40 minutes and 40–50 minutes 
in Figure 2) after formalin injection (Wilk’s λ = 0.868, 
F[1,33] = 5.037, P , 0.05). Specifically, male rats that 
received the drug displayed fewer pain-related behaviors 
than female rats that received drug.
On the other hand, male rats that received the drug before 
formalin injection showed significantly fewer pain-related 
behaviors compared with male rats that received saline 
at 0–10 minutes and 10–20 minutes after formalin injec-
tion, according to analysis of variance (Wilk’s λ = 0.39, 
F[2,11] = 8.63, P , 0.05). Female rats that received the drug 
before formalin injection also showed fewer pain-related 
behaviors compared with female rats that received saline 
at 0–10 minutes, according to analysis of variance (Wilk’s 
λ = 0.431, F[2,7] = 4.62, P , 0.05, see Figure 2).
Male rats that received the drug infusion after the for-
malin injection also displayed fewer pain-related behaviors 
compared with male rats that received the saline infusion 
at 30–40 minutes, based on analysis of variance (Wilk’s 
λ = 0.527, F[4,38] = 3.59, P , 0.05; post hoc test, P , 0.05). 
Moreover, male rats that received the drug before the for-
malin injection still displayed fewer pain-related behaviors 
compared with rats that received saline at 30–40 minutes 
(Wilk’s λ = 0.527, F[4,38] = 3.59, P , 0.05; post hoc test, 
P , 0.05, see Figure 2). Female rats that received the drug 
after the formalin injection also showed fewer pain-related 
behaviors compared with rats that received saline, but this 
difference did not reach statistical significance. In general, 
both male and female rats that received the drug before the 
formalin injection showed lower levels of inflammatory pain 
compared with those that received saline. Moreover, male 
rats that received the drug after the formalin injection showed 
fewer pain-related behaviors compared with their saline-
treated counterparts; however, female rats that received 
the drug after formalin injection showed fewer pain-related 
behaviors compared with female rats that received saline, 
but this tendency was not statistically significant.
Discussion
In this study, we found that Ro 25-6981 infusion was able 
to reduce formalin-induced pain-related behavior in both 
genders without affecting phasic pain responses. This study 
demonstrates that the analgesic action of NR2B antagonism 
(Ro 25-6981) applied at the level of the anterior cingulate 
cortex was able to reduce inflammatory pain levels in both 
male and female rats. A previous study by Wu et al reported 
a relationship between upregulation of NR2B receptors at 
the level of the anterior cingulate cortex and behavioral 
sensitization to inflammation in rodents, and that antago-
nism of NR2B in the anterior cingulate cortex reduced this 
sensitization.11 However, gender differences have not been 
explored in the context of antagonism of NR2B at the level 
of the anterior cingulate cortex. In the present study, a 
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Figure 1 Chart showing mean values of paw withdrawal latency in different groups of rats in the Hargreaves test. The paw withdrawal latency to thermal stimulus was 
measured in normal control rats, rats that received saline (vehicle) and rats that received Ro 25-6981.
Notes: Data are expressed as mean time (±standard error of the mean) in seconds of paw withdrawal latency after application of a heat stimulus to the hind paw. Repeated 
measures analysis of variance comparing rats that received saline and Ro 25-6981 did not find a time, gender, treatment, or interaction effect. Moreover, analysis of variance 
comparing rats that receive saline and control did not find gender nor treatment effects (P = not significant). *, &, @, $ means that the same animals were used for both time 
points (five minutes and 30 minutes).
Abbreviations: N Ctrl, naive control; Sal 5 m, saline applied at five minutes; Sal 30 m, saline applied at 30 minutes; Ro 5 m, Ro 25-6981 applied at five minutes; Ro 30 m, 
Ro 25-6981 applied at 30 minutes; SEM, standard error of the mean; PWL, paw withdrawal latency
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
304
Quintero et alJournal of Pain Research 2011:4
significant reduction in inflammatory pain was found if the 
drug was applied before formalin injection in both males and 
females, indicating no gender differences in the effects of the 
drug on the inflammatory pain response when Ro 25-6981 
is applied before formalin injection. However, the drug had 
a stronger analgesic effect in males than in females when 
administered after formalin injection. A possible explanation 
for this difference could be the estrogen hormone levels in 
female rodents; we used female rats in the estrus phase with 
a relatively high level of estrogen, and it has been shown that 
levels of estrogen and estrogen receptors (ERα and ERβ) can 
modulate pain-related behavior in female rodents in response 
to the formalin test.35–37
Other studies by Bereiter et al and Takeshita et al have 
shown that estrogen levels can modulate temporomandibular 
joint pain in animals and humans at the lower brainstem level, 
and also that estrogen levels affect morphine modulation of 
temporomandibular joint unit activity.38,39 Another study by 
Bereiter et al has shown that estrogen status could affect 
glutamatergic neurotransmission in the temporomandibular 
joint region by modulation of glutamate reuptake, and this 
could contribute to differences in pain response between 
males and females.40
We did not find any treatment or gender difference among 
the experimental groups tested with the phasic pain model 
(Hargreaves test), suggesting that NMDA antagonism at 
the anterior cingulate cortex level does not influence phasic 
responses in either gender. Our results also suggest that there 
were no adverse effects of stereotactic surgery on motor coor-
dination, because rats that received saline did not differ from 
the control rats in their latency response to thermal stimu-
lation. The phasic test for exploring side effects on motor 
coordination processes has also been used previously.3
The results of the present study are consistent with those 
of previous studies, ie, infusion of Ro 25-6981 in the anterior 
cingulate cortex is able to reduce tonic pain levels in male 
rodents. Wu et al have previously shown this in a complete 
adjuvant pain model, but add that antagonism of the   anterior 
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cingulate cortex NR2B receptors is also able to reduce inflam-
matory pain in female rodents.11 Moreover, like our present 
results, the research by Wu et al reported a lack of effect 
of Ro 25-6981 infusion in the anterior cingulate cortex on 
male phasic responses. Our study further demonstrated an 
absence of effect of Ro 25-6981 on phasic pain responses 
in females.
Our results are also in accord with other research using 
intracisternal administration of Ro 25-6981 in an orofacial 
formalin pain model (injection of formalin in the vibrissae),41 
which essentially showed reduction of tonic pain without side 
effects.41 The present results are also in agreement with the 
reduction of inflammatory pain levels and intact phasic pain 
response in neuropathic pain seen after electrolytic lesion of 
the anterior cingulate cortex.42
Furthermore, our study did not find marked gender 
differences in the effects of cortical administration of 
Ro 25-6981 in inflammatory pain if applied prior to forma-
lin injection. However, when Ro 25-6981 was applied after 
formalin injection, it had a stronger analgesic effect in males 
than in females.
The present results differ from those of another study 
showing, in particular, an absence of effects of another 
NMDA antagonist (AP5) on inflammatory pain levels after 
administration in the anterior cingulate cortex.43 In contrast, 
we found that administration of a NR2B antagonist before 
formalin injection reduced pain intensity. Differences in our 
results from those in the study of AP5 cortical administra-
tion could be explained by differences in the selectivity of 
the NMDA antagonist used, the study samples used, and the 
method used for behavior analysis (eg, automated recording 
versus scoring of licking/biting).43
The present study did not find any gender differences in 
the effects of Ro 25-6981 on phasic pain responses at the 
cortical level. Other studies that have explored the effects 
of Ro 25-6981 on phasic pain responses in male (but not 
female) rats have not found effects of Ro 25-6981 on the 
hot plate test (another test of phasic pain).44 Moreover, a 
further study found that Ro 25-6981 potentiated morphine 
analgesia in mice of both genders in a phasic pain model (tail 
flick test).45 It seems that Ro 25-6981 does not induce gender 
differences in phasic pain responses even when combined 
with other drugs.
In terms of connectivity, the possible circuit involved 
in the inhibitory effects of Ro 25-6981 on tonic pain 
found in this study could lie in the corticoreticular and 
corticoventromedullar pathways that have synapses at the 
dorsal horn levels of the spinal cord, and reduce pain input 
from the spinal cord.46,47 Indeed, studies on anterior cingulate 
cortex inhibition of visceral pain suggest that the anterior 
cingulate cortex could mediate inhibition or enhancement 
of spinal nociception via the dorsal reticular nucleus and 
rostral ventral medulla.48
Some investigators consider phosphorylation of the NR2B 
subunit to be responsible for induction and continuation of 
the sensitization process seen in neuropathic pain conditions, 
so future studies could explore antagonism of the NR2B sub-
unit at the anterior cingulate cortex level in other models of 
chronic pain, such as cancer pain, low back pain, and other 
newer models like chronic inflammatory joint pain.1,49,50 The 
novel contribution of this work is that it demonstrates the lack 
of a gender difference in antagonism of the NR2B subunit 
at the level of the anterior cingulate cortex with regard to 
the response to phasic pain, but does uncover some gender 
differences in the tonic inflammatory pain response. A limita-
tion of this study was the use of females in the estrus phase 
only. In conclusion, our study found that antagonism of the 
NR2B subunit at the level of the anterior cingulate cortex can 
reduce inflammatory pain levels without affecting phasic pain 
responses or motor responses in both female and male rats.
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Figure S1 (A) Injection sites (circles) for drug or vehicle infusion in the anterior cingulate cortex. (B) Injection sites (circles) for drug or vehicle infusion in the anterior 
cingulate cortex.
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